Zhao Yin Guo Ji·2026-04-01 05:12Macro Commentary - China's manufacturing PMI rebounded significantly in March, partly due to the later and longer Spring Festival holiday in 2026, although it remains in a contraction state based on the three-month moving average. Both supply and demand have improved significantly, with inventory cycles and import/export orders showing recovery [2] - The non-manufacturing PMI slightly increased, indicating a return to expansion in the service sector, while the construction sector remains in contraction. The price indices for both manufacturing and services suggest that upstream input inflation may lead to a positive PPI in the coming months [2] - The overall resilience of the RMB is maintained, fluctuating around 6.9 against the USD despite a strong dollar backdrop [4] Company Analysis Sunny Optical Technology (2382 HK) - The company is expected to achieve a revenue and net profit growth of 21% and 85% year-on-year in the second half of 2025, reaching RMB 23.6 billion and RMB 3 billion respectively. The net profit aligns with previous positive forecasts and exceeds market consensus by 44% due to a one-time investment gain from GoerTek [5] - Management guidance for 2026 indicates revenue and net profit growth of no less than 7% each, driven by a 5-10% increase in smartphone revenue and a 60% increase in IoT revenue, offsetting weakness in XR business [5] Yongda Automobile (3669 HK) - The company anticipates a significant impairment in 2025, with revenue expected to decline by 15% to RMB 27.5 billion in the second half of 2025, leading to a historical low overall gross margin of 7.0%. A total impairment of approximately RMB 4.9 billion is expected, resulting in a net loss of RMB 1.7 billion in the second half of 2025 [5] - Management plans to close 15-20 stores in 2026, with most related asset impairments already accounted for in 2025, suggesting no major impairments in 2026 [6] Sanofi Pharmaceutical (1530 HK) - The company is projected to achieve a revenue of RMB 17.7 billion in 2025, a 94.3% year-on-year increase, primarily due to a RMB 9.4 billion licensing income from Pfizer. However, product sales are expected to decline by 10.3% to RMB 8 billion due to national procurement policies [7] - The company is expected to maintain high levels of R&D investment to accelerate pipeline progress, with significant clinical advancements anticipated from the collaboration with Pfizer [8] Kanglong Chemical (300759 CH) - The company reported a 14.8% year-on-year revenue growth to RMB 14.1 billion in 2025, with adjusted net profit increasing by 13.0% to RMB 1.82 billion, both exceeding previous forecasts [10] - Management expects a revenue growth of 12-18% in 2026, with currency fluctuations negatively impacting growth guidance by 3 percentage points [11] Zhongji Xuchuang (300308 CH) - The company reported a strong FY25 performance with a revenue growth of 60% to RMB 38.2 billion and a net profit increase of 109% to RMB 10.8 billion, aligning with market expectations [14] - The gross margin improved significantly from 34.7% in FY24 to 42.6% in FY25, driven by strong shipments of high-speed optical modules and an increase in the proportion of silicon photonics products [14] OmniVision Technologies (603501 CH) - The company achieved a revenue growth of 12.1% to RMB 28.9 billion in FY25, with a net profit increase of 21.7% to RMB 4 billion, although slightly below market expectations [15] - The gross margin improved from 29.4% in FY24 to 30.6% in FY25, primarily due to the optimization of CIS product structure and increased contributions from automotive CIS revenue [15]